Myopia
Conditions
Interventions
Myopia prevention group by LLLT:Low-level red-light therapy
Myopia retardation group by LLLT:Single vision spectacle lens combined with Low-level red-light therapy
Myopia prevention group by Low concentration atropine eye drops:Low concentration(0.02%) atropine eye drops
Myopia retardation group by Low concentration atropine eye drops:Single vision spectacle lens combined with Low concentration(0.02%) atropine eye drops
Myopia prevention control group:None
Myopia retardation control group:Single vision spectacle lens
Sponsors
Department of Ophthalmology, the First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 14 Years
Inclusion criteria
Inclusion criteria: (1) Initial spherical equivalent ranged of -6.00D to +0.50D, and astigmatism <= 1.0D. (2) Recruited children age was between 6 to 14 years, willing to participate in the entire 2-year trial. (3) Binocular function and stereopsis were normal. (4) Intraocular pressure was normal (IOP<21 mmHg). (5) Ability against cycloplegia was a must.
Exclusion criteria
Exclusion criteria: (1) Children with ocular diseases, such as amblyopia, strabismus, congenital cataract, glaucoma, corneal scar, optic neuropathy, traumatic ocular injury, uveitis, or ocular tumor were excluded. (2) Children with history of any ocular surgeries were excluded. (3) Any systemic diseases or conditions that could affect visual function and development, including diabetes mellitus and/or chromosome anomaly, were excluded. (4) Previous or current use of contact lenses, bifocals, progressive addition lenses, or other forms of treatment, including atropine, for the control of myopia were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Axial length (AL);Cycloplegic spherical equivalent change;Choroidal thickness;Choroidal vascular density; | — |
Secondary
| Measure | Time frame |
|---|---|
| Corneal curvature;Anterior chamber depth;Visual acuity;Peripheral retinal defocus;Intraocular pressure;Incidence of treatment-emergent adverse events;The corneal thickness;Corneal endothelial cell count; | — |
Countries
China
Contacts
Public ContactHua Zhong
Department of Ophthalmology, the First Affiliated Hospital of Kunming Medical University
Outcome results
None listed